Anish Patel Sells 6,667 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $17.40, for a total value of $116,005.80. Following the sale, the chief operating officer owned 269,974 shares of the company’s stock, valued at approximately $4,697,547.60. This trade represents a 2.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Anish Patel also recently made the following trade(s):

• On Tuesday, October 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.10, for a total value of $134,006.70.
• On Monday, September 8th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.24, for a total value of $134,940.08.

Enliven Therapeutics Stock Down 0.1%

Shares of ELVN stock opened at $20.27 on Friday. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $27.20. The business’s 50 day moving average is $20.19 and its two-hundred day moving average is $20.05. The company has a market cap of $1.20 billion, a PE ratio of -11.02 and a beta of 0.80.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. As a group, equities analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Enliven Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.20.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its stake in shares of Enliven Therapeutics by 61.3% in the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock valued at $4,167,000 after buying an additional 80,506 shares during the period. Wellington Management Group LLP raised its holdings in Enliven Therapeutics by 4.7% in the 1st quarter. Wellington Management Group LLP now owns 84,700 shares of the company’s stock valued at $1,667,000 after acquiring an additional 3,784 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Enliven Therapeutics by 148,550.7% in the 1st quarter. Russell Investments Group Ltd. now owns 105,542 shares of the company’s stock worth $2,077,000 after acquiring an additional 105,471 shares during the period. Ally Bridge Group NY LLC grew its holdings in shares of Enliven Therapeutics by 19.8% during the 1st quarter. Ally Bridge Group NY LLC now owns 169,774 shares of the company’s stock worth $3,341,000 after purchasing an additional 28,064 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Enliven Therapeutics during the 1st quarter worth approximately $2,049,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.